Noopept

Adera

$50.00

0mg · spray

Noopept's mechanism of action is multifaceted and — despite decades of research — incompletely understood. Several convergent pathways have been proposed, each supported by preclinical data but none definitively established as the primary driver of its clinical effects.

Cycloprolylglycine metabolite hypothesis. The most widely cited mechanistic model holds that Noopept is a prodrug for cycloprolylglycine (cPG), an endogenous dipeptide found in mammalian brain tissue. Upon oral administration, Noopept is rapidly metabolised by peptidases, releasing cPG, which is thought to mimic or potentiate endogenous neuropeptide signalling. Cycloprolylglycine has structural similarity to the endogenous oxytocin-like peptides and to pyroglutamyl peptides involved in memory and stress responses. Work by Ostrovskaya and colleagues suggests that cPG levels rise after Noopept administration and correlate with its pharmacological effects. Whether cPG itself accounts for all of Noopept's activity or whether the parent molecule also acts directly remains debated.

Neurotrophic factor modulation. Several rodent studies report that Noopept administration upregulates the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex. BDNF and NGF are critical for synaptic plasticity, long-term potentiation (LTP), and the survival of cholinergic neurons — all processes implicated in memory consolidation and resistance to neurodegenerative stress. Ostrovskaya et al. (2008) reported that chronic Noopept administration increased BDNF and NGF mRNA in rat brains, with effects most pronounced in the hippocampus. This is a plausible mechanism for the memory-improving and neuroprotective claims, but the magnitude of the effect and its translation to humans is uncertain. Similar BDNF-upregulation claims have been made for exercise, ketamine, SSRIs, and numerous other interventions, making specificity difficult to establish.

AMPA and NMDA receptor modulation. Noopept has been reported to positively modulate AMPA receptor function and to sensitise hippocampal neurons to glutamatergic signalling without causing the excitotoxicity associated with direct agonism. This would be consistent with enhanced long-term potentiation and improved memory consolidation. The racetam family (piracetam, aniracetam, oxiracetam) is thought to share this mechanism, though the exact molecular target is still debated — proposed candidates include allosteric sites on AMPA receptors, modulation of TARP (transmembrane AMPA receptor regulatory protein) auxiliary subunits, and effects on glutamate release.

Cholinergic potentiation. Some studies report that Noopept enhances acetylcholine release in cortical and hippocampal regions, which is consistent with its use (in Russia) for cognitive decline in elderly patients with cerebrovascular disease. This mechanism overlaps conceptually with the cholinesterase inhibitors (donepezil, rivastigmine, galantamine) used in Alzheimer's disease, though Noopept is not a direct cholinesterase inhibitor and its cholinergic effects appear to be indirect.

Anxiolytic mechanism. Noopept's anxiolytic effects — reported in both animal models and Russian clinical trials — may derive from cPG-mediated modulation of the HPA axis and GABAergic tone, or from its broader neurotrophic effects on prefrontal-amygdala circuits implicated in anxiety regulation. This is less well characterised mechanistically than its pro-cognitive effects.

Neuroprotection and antioxidant effects. A substantial body of rodent work reports that Noopept protects neurons from oxidative stress, excitotoxicity (glutamate, kainate), and ischaemia-reperfusion injury. Proposed mechanisms include upregulation of endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase), inhibition of mitochondrial permeability transition pore opening, and reduction of calcium-mediated excitotoxic cascades. These effects have been demonstrated in cell culture and animal models but have not been translated to human clinical trials of neuroprotection.

What Noopept is NOT. Noopept is not a psychostimulant — it does not produce the subjective alertness, euphoria, or wakefulness of amphetamines, methylphenidate, or modafinil, and it does not appreciably affect dopaminergic signalling in the reward pathway. It is not a GABAergic anxiolytic — it does not bind the benzodiazepine site, does not potentiate GABA-A receptor currents at typical doses, and does not produce the sedation or motor impairment of benzodiazepines. It is not a serotonergic drug — it does not inhibit serotonin reuptake, does not activate serotonin receptors, and should not produce serotonin syndrome when combined with SSRIs. Its pharmacology sits outside the standard psychiatric drug categories, which is part of both its appeal and its mystery.

Noopept is the common brand and research name for N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111; INN omberacetam), a small dipeptide nootropic developed in the 1990s at the Russian Academy of Medical Sciences' Institute of Pharmacology under Tatiana Voronina and Rita Ostrovskaya. Structurally, Noopept is a cyclized prolylglycine derivative conjugated to a phenylacetyl group, giving it roughly a thousand-fold higher potency than piracetam on a per-milligram basis while retaining some mechanistic overlap with the racetam family. It is sold over-the-counter in Russia as a cognitive enhancer and anxiolytic (trade name Noopept, manufactured by JSC Lekko Pharmaceuticals under license from the Zakusov Institute), where it carries approvals for post-concussive syndrome, cerebrovascular insufficiency, and mild to moderate cognitive decline. Outside Russia and a handful of CIS states, Noopept has no regulatory status — it is not approved as a drug in the United States, the United Kingdom, the European Union, Canada, or Australia, and it is not listed on any pharmacopoeia as a recognised medicine. It has been scheduled as a controlled or prohibited substance in a small number of jurisdictions (notably the Czech Republic) but in most Western countries it exists in a legal grey zone: neither an approved drug nor a regulated supplement, often sold online as a "research chemical" or nootropic powder.

The compound's appeal rests on three overlapping claims — that it enhances memory consolidation, that it produces a mild anxiolytic effect, and that it is neuroprotective against oxidative, excitotoxic, and ischaemic insults. Each of these claims has some experimental support in rodent models and a small body of Russian clinical literature, but the evidence base is markedly thinner than for any drug approved in the West for cognitive impairment or anxiety. The key studies are mostly Soviet-era and post-Soviet Russian publications indexed on eLibrary.ru and — in a minority of cases — on PubMed, often with methodology that would not meet contemporary ICH-GCP or FDA standards. Randomised, double-blind, placebo-controlled trials with pre-registered endpoints, intention-to-treat analysis, and independent replication — the evidentiary bedrock of Western drug approval — are largely absent. This does not mean Noopept "doesn't work," but it does mean that anyone using it is relying on a body of evidence that would be considered hypothesis-generating rather than definitive by regulators at the FDA, EMA, MHRA, or Health Canada.

For context, the drugs with the strongest evidence base for true cognitive impairment — Alzheimer's disease and related dementias — are the cholinesterase inhibitors donepezil, rivastigmine, and galantamine, and the NMDA receptor modulator memantine. These agents have been tested in thousands of patients in rigorously controlled trials and show modest but reproducible effects on cognition and activities of daily living. Newer disease-modifying therapies like lecanemab and donanemab target beta-amyloid pathology directly and have demonstrated reductions in cognitive decline in prodromal and mild Alzheimer's disease. Noopept is not a substitute for any of these drugs, and anyone experiencing genuine cognitive decline should be evaluated by a neurologist or geriatric psychiatrist rather than self-medicating with an unregulated Russian nootropic.

For subclinical complaints — the "brain fog" and mild age-related cognitive slowing that prompt many healthy adults to try nootropics — the evidence for Noopept is weaker still. Most human trials were conducted in patients with documented cerebrovascular disease, post-traumatic cognitive impairment, or neurasthenic syndromes, not in healthy young adults seeking cognitive enhancement. Extrapolating from a 60-year-old Russian stroke patient to a 28-year-old programmer wanting sharper focus is a substantial leap that the data do not support. What Noopept offers healthy users — according to self-report and a handful of small Russian studies — is a subtle, often described as "subthreshold" improvement in mental clarity, mood, and stress tolerance, particularly when combined with an alcar/choline source to offset headaches. Whether this exceeds placebo in a properly blinded trial is an open question.

Noopept's legal and regulatory status merits careful attention. It is unscheduled in the United States but is not recognised as a dietary supplement under DSHEA, meaning it is technically illegal to sell as a supplement though enforcement has been inconsistent. It is a prescription-only medication in Russia and several CIS states. In the European Union, it is generally treated as a novel food ingredient or an unregistered drug depending on the member state. It is banned or restricted in the Czech Republic, Hungary, and a few other countries. Anyone sourcing Noopept online should understand that they are purchasing an unregulated powder or capsule from a vendor whose quality control is unverifiable. Identity, purity, and dosing accuracy should be assumed to be uncertain unless third-party certificates of analysis (HPLC, mass spectrometry) are provided. Other nootropics in the same general category — selank and semax — share similar Russian origins and evidentiary limitations. For a more evidence-based approach to cognitive enhancement, see the literature on modafinil (prescription wakefulness agent with solid trial data for shift-work disorder and narcolepsy), methylene-blue, nad, or lifestyle interventions (sleep, exercise, nutrition) that have substantially more rigorous supporting evidence.

IUPAC Name

N-phenylacetyl-L-prolylglycine ethyl ester

CAS Number

157115-85-0

Molecular Formula

C17H22N2O4

Molecular Mass

318.37 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Noopept Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it. Current lowest: $50.00

Related Compounds

Side-by-Side Comparisons

Related Articles

Adera

$50.00

Data Completeness

Research Credibility